Bisoxatin acetate

A cell-permeable azobenzene compound that reversibly targets CREB-binding protein bromodomain (CBP-BRD) acetyl-lysine binding pocket (K d = 19 &#181M) with moderate selectivity over BAZ1B, PCAF, BRD4-1 and BAZ2B (K d = 37, 41, 70 and &gt100

Peptone from gelatin, enzymatic digest

PrEST Antigen ACIN1 apoptotic chromatin condensation inducer

Biochem/physiol Actions Santacruzamate A (CAY10683) is a cell-permeable and bioavailable carbamate compound that potently inhibits HDAC2 (IC50 = 119 nM) selectively over HDAC4 and HDAC6 (IC50 = &gt: 1 &#956:M and 433.5 nM, respectively).

Biochem/physiol Actions Santacruzamate A (CAY10683) is a cell-permeable and bioavailable carbamate compound that potently inhibits HDAC2 (IC50 = 119 nM) selectively over HDAC4 and HDAC6 (IC50 = &gt: 1 &#956:M and 433.5 nM, respectively).

A non-peptide that acts as a selective, high affinity, competitive antagonist of the anaphylatoxin C3a receptor (IC 50 = 200 nM). Does not antagonize C5aR or other chemotactic G-protein-coupled receptors.

A short chain fatty acid that has been shown to induce apoptosis in colon carcinoma cell lines by a p53-independent pathway. Inhibits c- myc splicing and interferes with signal transduction processes, including the release of Ca 2+ from

Application Trapoxin A has been used: to study its effects on the inhibition of histone deacetylase 11 (HDAC11) to study its effects on the inhibition of HDAC3 in human cell lines to study its effects on the inhibition of HDAC6 in rat

Application Trapoxin A has been used: to study its effects on the inhibition of histone deacetylase 11 (HDAC11) to study its effects on the inhibition of HDAC3 in human cell lines to study its effects on the inhibition of HDAC6 in rat